Acne is the most common disorder seen by dermatologists today. In darker skin types (Fitzpatrick IV-VI), post-inflammatory hyperpigmentation (PIH) is a frequent sequel to acne, and may be emotionally devastating to patients. Treatment consists of topical retinoids and antimicrobial agents to address both inflammatory and non-inflammatory acne lesions. The gold standard for treatment for PIH is hydroquinone-containing products that can be used alone or in combination to reverse the pigmentary changes. This 12-week, open-label study examined the use of adapalene cream and a triple-combination depigmenting formulation containing tretinoin, hydroquinone, and fluocinolone acetonide in the treatment of mild-to-moderate acne and PIH. Subjects included 10 patients with skin types IV-VI. Evaluations were made by means of photography and mexameter reading to assess hyperpigmented macules at baseline and at weeks 2,4,8, and 12. The patients used adapalene cream once daily in the morning for 12 weeks and the triple-combination cream once daily in the evening for 8 weeks. Patients were instructed to use a mild cleanser twice daily, a moisturizers with SPF15 once daily in the morning and a moisturizer cream or lotion, as needed. Efficacy endpoints include investigators global assessments, total lesion counts, inflammatory and non-inflammatory lesion counts, and hyperpigmented macules. Safety endpoints include erythema, dyspigmentation, scaling, itching, burning, skin irritation, telangiectasia, and atrophy. Regarding to quality of life, results of a patient survey that scored feelings regarding their treatment, their condition and how it affects various aspects of their life, and rating of their improvement will also be discussed.